Key Drivers
- Strong EBITDA
- High leverage
- Low net margin
AIAI Summary
GRFS is a conditional recovery trade—improving free cash flow and cost savings make deleveraging and dividends plausible, but very high absolute leverage (~$9.2B) means investor outcomes now hinge almost entirely on rapid remediation of plasma collection compliance and litigation outcomes. Require concrete milestones (sustained FCF >$320M, demonstrable collection-center remediation, and realization of the €450M savings) before treating this as a low‑risk dividend play, since regulatory or donor‑supply setbacks could quickly erase equity value.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong EBITDA
- •High leverage
- •Low net margin
GRFS delivers strong revenue, gross and EBITDA margins with positive free cash flow, but heavy debt, large intangibles and high interest costs compress net income and raise solvency risk.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •Deeply oversold RSI
- •Lower highs/lows
GRFS is in a short-term downtrend trading below its last month SMA (~$8.50) at $7.58 with RSI ~22 (deeply oversold) suggesting selling pressure but a possible bounce into the $8.7–$9.4 resistance zone.
Drop from ~$9.40 peak in mid-February into current $7.58 low indicating accelerated short-term decline
Sentiment & News
Key News Insights:
- •Double-digit profit
- •Parkinson's data
- •Plasma compliance
Grifols posted strong 2025 financial and research gains—including doubled net profit, cost-savings upside, and promising Parkinson's proof-of-concept data—while facing serious safety, legal and compliance issues at plasma centers.
Positive earnings and research momentum could bolster valuation, but operational and safety risks may keep volatility and downside risk for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings